Mytolac (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors, especially SSTR2 and SSTR5. This binding blocks intracellular signaling pathways that trigger hormone release, thereby reducing levels of growth hormone, insulin, glucagon, and other peptides involved in the targeted diseases.

The dosage of Mytolac is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Healthcare professionals determine the appropriate amount, frequency, and duration of treatment according to current clinical guidelines.

Safety data for Mytolac in pregnancy and lactation are limited, and the product’s pregnancy category is not established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To request Mytolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Mytolac (lanreotide acetate) and other somatostatin analogues such as octreotide share a similar mechanism of receptor binding but differ in formulation, dosing frequency, and pharmacokinetic profile. Lanreotide often allows for longer dosing intervals, which can improve patient convenience, while efficacy and safety are comparable when used appropriately.

Mytolac should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keeping the product in its original packaging helps maintain stability and ensures potency until the point of administration.

Mytolac is given by subcutaneous injection, typically performed by a healthcare professional or a trained patient/caregiver. The injection is administered into the fatty tissue of the abdomen or thigh, following aseptic technique and the specific instructions provided by the prescriber.

Serious adverse events linked to Mytolac include gallstone formation, acute pancreatitis, severe allergic reactions (including anaphylaxis), and cardiac arrhythmias. Patients should be monitored for signs such as severe abdominal pain, jaundice, difficulty breathing, or irregular heartbeat, and seek immediate medical attention if these occur.

Mytolac is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is also advised for individuals with uncontrolled diabetes, active gallbladder disease, or severe cardiac conditions, and it should be avoided in those where the risk outweighs potential benefit.